Home » Authors » Brady Huggett

Articles by Brady Huggett

Indevus' Trospium Phase III Hits Primary, Secondary Endpoints

Sep. 25, 2002

By Brady Huggett

Indevus' Trospium Phase III Hits Primary, Secondary Endpoints

Sep. 25, 2002

By Brady Huggett

Kosan Signs $220M Deal With Roche For KOS-862 Cancer Drug

Sep. 24, 2002

By Brady Huggett

Kosan Signs $220M Deal With Roche For KOS-862 Cancer Drug

Sep. 24, 2002

By Brady Huggett

CellGate Closes $10M Series D, Aims For 2003 PsorBan Phase III

Sep. 23, 2002

By Brady Huggett

Bio-Technology General To Buy Rosemont For $99M In Cash

Sep. 23, 2002

By Brady Huggett

CombinatoRx Raises $40M In Series C To Fund Clinical Trials

Sep. 23, 2002

By Brady Huggett

CellGate Closes $10M Series D, Aims For 2003 PsorBan Phase III

Sep. 23, 2002

By Brady Huggett

CombinatoRx Raises $40M In Series C To Fund Clinical Trials

Sep. 23, 2002

By Brady Huggett

Bio-Technology General To Buy Rosemont For $99M In Cash

Sep. 23, 2002

By Brady Huggett

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
ASH 2025: Ianalumab data offer break from chronic ITP therapy
BioWorld
Novartis AG’s monoclonal antibody, ianalumab (VAY-736), when added to standard-of-care eltrombopag, extended disease control of primary immune thrombocytopenia...